Cargando…

Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors

Triple-negative breast cancer (TNBC) is a type of breast tumor that currently lacks options for targeted therapy. Tremendous effort has been made to identify treatment targets for TNBC. Here, we report that the expression level of anaphase promoting complex (APC) coactivator Cdh1 in TNBC is elevated...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Junjun, Lan, Mengjiao, Peng, Jin, Xiong, Qunli, Xu, Yongfeng, Yang, Yang, Zhou, Ying, Liu, Jinlu, Zeng, Zhu, Yang, Xiaojuan, Zhang, Zhiwei, Zhang, Pumin, Zhu, Qing, Wu, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141497/
https://www.ncbi.nlm.nih.gov/pubmed/35627188
http://dx.doi.org/10.3390/genes13050803
_version_ 1784715360160710656
author Li, Junjun
Lan, Mengjiao
Peng, Jin
Xiong, Qunli
Xu, Yongfeng
Yang, Yang
Zhou, Ying
Liu, Jinlu
Zeng, Zhu
Yang, Xiaojuan
Zhang, Zhiwei
Zhang, Pumin
Zhu, Qing
Wu, Wei
author_facet Li, Junjun
Lan, Mengjiao
Peng, Jin
Xiong, Qunli
Xu, Yongfeng
Yang, Yang
Zhou, Ying
Liu, Jinlu
Zeng, Zhu
Yang, Xiaojuan
Zhang, Zhiwei
Zhang, Pumin
Zhu, Qing
Wu, Wei
author_sort Li, Junjun
collection PubMed
description Triple-negative breast cancer (TNBC) is a type of breast tumor that currently lacks options for targeted therapy. Tremendous effort has been made to identify treatment targets for TNBC. Here, we report that the expression level of anaphase promoting complex (APC) coactivator Cdh1 in TNBC is elevated compared to that in the adjacent healthy tissues, and high levels of Cdh1 expression are correlated with poor prognoses, suggesting that Cdh1 contributes to the progression of TNBC. Interfering with the function of Cdh1 can potentiate the cytotoxic effects of PARP inhibitors against BRCA-deficient and BRCA-proficient TNBC cells through inducing DNA damage, checkpoint activation, cell cycle arrest, and apoptosis. Further investigation reveals that Cdh1 promotes BRCA1 foci formation and prevents untangled DNA entering mitosis in response to PARP inhibition (PARPi) in TNBC cells. Collectively, these results suggest that APC/Cdh1 is a potential molecular target for PARPi-based therapies against TNBCs.
format Online
Article
Text
id pubmed-9141497
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91414972022-05-28 Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors Li, Junjun Lan, Mengjiao Peng, Jin Xiong, Qunli Xu, Yongfeng Yang, Yang Zhou, Ying Liu, Jinlu Zeng, Zhu Yang, Xiaojuan Zhang, Zhiwei Zhang, Pumin Zhu, Qing Wu, Wei Genes (Basel) Article Triple-negative breast cancer (TNBC) is a type of breast tumor that currently lacks options for targeted therapy. Tremendous effort has been made to identify treatment targets for TNBC. Here, we report that the expression level of anaphase promoting complex (APC) coactivator Cdh1 in TNBC is elevated compared to that in the adjacent healthy tissues, and high levels of Cdh1 expression are correlated with poor prognoses, suggesting that Cdh1 contributes to the progression of TNBC. Interfering with the function of Cdh1 can potentiate the cytotoxic effects of PARP inhibitors against BRCA-deficient and BRCA-proficient TNBC cells through inducing DNA damage, checkpoint activation, cell cycle arrest, and apoptosis. Further investigation reveals that Cdh1 promotes BRCA1 foci formation and prevents untangled DNA entering mitosis in response to PARP inhibition (PARPi) in TNBC cells. Collectively, these results suggest that APC/Cdh1 is a potential molecular target for PARPi-based therapies against TNBCs. MDPI 2022-04-30 /pmc/articles/PMC9141497/ /pubmed/35627188 http://dx.doi.org/10.3390/genes13050803 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Li, Junjun
Lan, Mengjiao
Peng, Jin
Xiong, Qunli
Xu, Yongfeng
Yang, Yang
Zhou, Ying
Liu, Jinlu
Zeng, Zhu
Yang, Xiaojuan
Zhang, Zhiwei
Zhang, Pumin
Zhu, Qing
Wu, Wei
Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
title Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
title_full Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
title_fullStr Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
title_full_unstemmed Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
title_short Cdh1 Deficiency Sensitizes TNBC Cells to PARP Inhibitors
title_sort cdh1 deficiency sensitizes tnbc cells to parp inhibitors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9141497/
https://www.ncbi.nlm.nih.gov/pubmed/35627188
http://dx.doi.org/10.3390/genes13050803
work_keys_str_mv AT lijunjun cdh1deficiencysensitizestnbccellstoparpinhibitors
AT lanmengjiao cdh1deficiencysensitizestnbccellstoparpinhibitors
AT pengjin cdh1deficiencysensitizestnbccellstoparpinhibitors
AT xiongqunli cdh1deficiencysensitizestnbccellstoparpinhibitors
AT xuyongfeng cdh1deficiencysensitizestnbccellstoparpinhibitors
AT yangyang cdh1deficiencysensitizestnbccellstoparpinhibitors
AT zhouying cdh1deficiencysensitizestnbccellstoparpinhibitors
AT liujinlu cdh1deficiencysensitizestnbccellstoparpinhibitors
AT zengzhu cdh1deficiencysensitizestnbccellstoparpinhibitors
AT yangxiaojuan cdh1deficiencysensitizestnbccellstoparpinhibitors
AT zhangzhiwei cdh1deficiencysensitizestnbccellstoparpinhibitors
AT zhangpumin cdh1deficiencysensitizestnbccellstoparpinhibitors
AT zhuqing cdh1deficiencysensitizestnbccellstoparpinhibitors
AT wuwei cdh1deficiencysensitizestnbccellstoparpinhibitors